scholarly journals Tight junction protein gene expression patterns and changes in transcript abundance during development of model fish gill epithelia

2014 ◽  
Vol 217 (10) ◽  
pp. 1667-1681 ◽  
Author(s):  
D. Kolosov ◽  
H. Chasiotis ◽  
S. P. Kelly
Keyword(s):  
Gene Expression ◽  
Tight Junction ◽  
Protein Gene ◽  
Expression Patterns ◽  
Transcript Abundance ◽  
Tight Junction Protein ◽  
Gene Expression Patterns ◽  
Fish Gill ◽  
Junction Protein ◽  
Model Fish

The Tight Junction Protein Cingulin Regulates Gene Expression and RhoA Signaling

2009 ◽  
Vol 1165 (1) ◽  
pp. 88-98 ◽  
Author(s):  
Sandra Citi ◽  
Serge Paschoud ◽  
Pamela Pulimeno ◽  
Francesco Timolati ◽  
Fabrizio De Robertis ◽  
...  
Keyword(s):  
Gene Expression ◽  
Tight Junction ◽  
Tight Junction Protein ◽  
Junction Protein ◽  
Rhoa Signaling

Localization of the Tight Junction Protein Gene TJP1 to Human Chromosome 15q13, Distal to the Prader-Willi/Angelman Region, and to Mouse Chromosome 7

Genomics ◽  
1995 ◽  
Vol 30 (3) ◽  
pp. 594-597 ◽  
Author(s):  
T.K. Mohandas ◽  
X.-N. Chen ◽  
L.B. Rowe ◽  
E.H. Birkenmeier ◽  
A.S. Fanning ◽  
...  
Keyword(s):  
Human Chromosome ◽  
Tight Junction ◽  
Mouse Chromosome ◽  
Protein Gene ◽  
Tight Junction Protein ◽  
Chromosome 7 ◽  
Junction Protein

scholarly journals Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Emanuela Fina ◽  
Andrea Necchi ◽  
Stefano Bottelli ◽  
Carolina Reduzzi ◽  
Sara Pizzamiglio ◽  
...  
Keyword(s):  
Gene Expression ◽  
Blood Cells ◽  
Protein Gene ◽  
Expression Patterns ◽  
Tumour Cells ◽  
Gene Expression Patterns ◽  
Circulating Tumour Cells ◽  
Clinical Validity ◽  
Clinical Correlations ◽  
Time Point

Circulating tumour cells (CTC) are identified exploiting their protein/gene expression patterns or distinct size compared to blood cells. Data on CTC in bladder cancer (BC) are still scarce. We comparatively analyzed CTC enrichment by AdnaTest ProstateCancerSelect (AT) and ScreenCell®Cyto (SC) kits, combined with identification by EPCAM, MUC1, and ERBB2 expression and by cytological criteria, respectively, in 19 nonmetastatic (M0) and 47 metastatic (M+) BC patients, at baseline (T0) and during treatment (T1). At T0, CTC positivity rates by AT were higher in M+ compared to M0 cases (57.4% versus 25%, p = 0.041). EPCAM was detected in 75% of CTC-positive samples by AT, showing increasing expression levels from T0 to T1 (median (interquartile range, IQR): 0.18 (0.07–0.42) versus 0.84 (0.33–1.84), p=0.005) in M+ cases. Overall, CTC positivity by SC was around 80% regardless of clinical setting and time point of analysis, except for a lower occurrence at T1 in M0 cases. At T0, circulating tumour microemboli were more frequently (25% versus 8%) detected and more numerous in M+ compared to M0 patients. The approach used for CTC detection impacts the outcome of CTC studies. Further investigations are required to clarify the clinical validity of AT and SC in specific BC clinical contexts.

Sign in / Sign up

Export Citation Format

Share Document